Dr Boby Mihaylova
Associate Professor and University Research Lecturer
- Health Economics Research Centre
Borislava (Boby) Mihaylova is a University Research Lecturer and a Senior Researcher in Health Economics at the Health Economics Research Centre at the University of Oxford. Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She is leading the development of the economic analyses in a number of large randomised controlled trials (SHARP, THRIVE, REVEAL and ACST-2) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
Herrington WG. et al, (2018), J Am Soc Nephrol
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.
Marthi A. et al, (2018), J Am Soc Nephrol, 29, 2015 - 2027
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment.
Jepson M. et al, (2018), J Clin Epidemiol, 99, 75 - 83
Impact of CKD on Household Income.
Morton RL. et al, (2018), Kidney Int Rep, 3, 610 - 618
Meta-analysis of the procedural risks of carotid endarterectomy and carotid artery stenting over time.
Lokuge K. et al, (2018), British Journal of Surgery, 105, 26 - 36